Federated Hermes, Inc. Scholar Rock Holding Corp Transaction History

Federated Hermes, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$6.52 - $20.32 $3,494 - $10,891	536 New	536 $10,000
Q2 2022 Aug 15, 2022	BUY	$4.66 - $13.96 $153 - $460	33 Added 132.0%	58 $1,000
Q1 2022 May 13, 2022	SELL	$11.89 - $24.68 $219,132 - $454,852	-18,430 Reduced 99.86%	25 $1,000
Q4 2021 Feb 14, 2022	SELL	$24.14 - $35.18 $7.4 Million - $10.8 Million	-306,545 Reduced 94.32%	18,455 $458,000
Q2 2021 Aug 16, 2021	SELL	$26.34 - $46.62 $311,417 - $551,188	-11,823 Reduced 3.51%	325,000 $9.39 Million
Q1 2021 May 13, 2021	BUY	$45.96 - $68.02 $5.14 Million - $7.6 Million	111,734 Added 49.64%	336,823 $17.1 Million
Q4 2020 Feb 12, 2021	BUY	$13.72 - $51.57 $1.03 Million - $3.86 Million	74,799 Added 49.77%	225,089 $10.9 Million
Q3 2020 Nov 12, 2020	BUY	$10.54 - $18.47 $124,034 - $217,354	11,768 Added 8.5%	150,290 $2.66 Million
Q2 2020 Aug 13, 2020	BUY	$10.37 - $20.64 $1.43 Million - $2.85 Million	138,313 Added 66178.47%	138,522 $2.52 Million
Q1 2020 May 13, 2020	BUY	$9.63 - $17.14 $1,954 - $3,479	203 Added 3383.33%	209 $3,000
Q4 2019 Feb 14, 2020	SELL	$7.2 - $13.2 $14,882 - $27,284	-2,067 Reduced 99.71%	6 $1,000
Q3 2019 Nov 14, 2019	BUY	$8.95 - $15.72 $1,754 - $3,081	196 Added 10.44%	2,073 $19,000
Q2 2019 Aug 14, 2019	SELL	$14.61 - $22.45 $24,837 - $38,165	-1,700 Reduced 47.53%	1,877 $30,000
Q1 2019 May 10, 2019	BUY	$14.24 - $22.28 $10,680 - $16,710	750 Added 26.53%	3,577 $67,000
Q4 2018 Feb 13, 2019	BUY	$17.86 - $28.77 $50,490 - $81,332	2,827 New	2,827 $64,000

175

75.6M

585K

862K

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $2.17B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.